277 related articles for article (PubMed ID: 10993031)
21. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
[TBL] [Abstract][Full Text] [Related]
22. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
[TBL] [Abstract][Full Text] [Related]
23. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.
Villareal DT; Binder EF; Williams DB; Schechtman KB; Yarasheski KE; Kohrt WM
JAMA; 2001 Aug; 286(7):815-20. PubMed ID: 11497535
[TBL] [Abstract][Full Text] [Related]
24. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
25. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
26. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
Rosen CJ; Chesnut CH; Mallinak NJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
[TBL] [Abstract][Full Text] [Related]
28. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women.
Maddalozzo GF; Widrick JJ; Cardinal BJ; Winters-Stone KM; Hoffman MA; Snow CM
Bone; 2007 May; 40(5):1244-51. PubMed ID: 17291843
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
Warming L; Ravn P; Nielsen T; Christiansen C
Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
[TBL] [Abstract][Full Text] [Related]
30. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
[TBL] [Abstract][Full Text] [Related]
31. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
[TBL] [Abstract][Full Text] [Related]
32. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
33. Does apolipoprotein E genotype relate to BMD and bone markers in postmenopausal women?
Heikkinen AM; Kröger H; Niskanen L; Komulainen MH; Ryynänen M; Parviainen MT; Tuppurainen MT; Honkanen R; Saarikoski S
Maturitas; 2000 Jan; 34(1):33-41. PubMed ID: 10687880
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of two dosages of a continuous combined hormone replacement regimen.
Loh FH; Chen LH; Yu SL; Jorgensen LN
Maturitas; 2002 Feb; 41(2):123-31. PubMed ID: 11836043
[TBL] [Abstract][Full Text] [Related]
35. Effect of 10 years' hormone replacement therapy on bone mineral content in postmenopausal women.
Eiken P; Kolthoff N; Nielsen SP
Bone; 1996 Nov; 19(5 Suppl):191S-193S. PubMed ID: 8922661
[TBL] [Abstract][Full Text] [Related]
36. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.
Wang C; Eyre DR; Clark R; Kleinberg D; Newman C; Iranmanesh A; Veldhuis J; Dudley RE; Berman N; Davidson T; Barstow TJ; Sinow R; Alexander G; Swerdloff RS
J Clin Endocrinol Metab; 1996 Oct; 81(10):3654-62. PubMed ID: 8855818
[TBL] [Abstract][Full Text] [Related]
37. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
38. The benefit of hormone replacement therapy on bone mass is greater at the vertebral body than posterior processes or proximal femur.
Duan Y; Tabensky A; DeLuca V; Seeman E
Bone; 1997 Nov; 21(5):447-51. PubMed ID: 9356739
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Alexandersen P; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042
[TBL] [Abstract][Full Text] [Related]
40. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.
Delmas PD; Marianowski L; Perez Ade C; Ribot C; Pornel B; Palacios S; Lopes P;
Maturitas; 2004 Jun; 48(2):85-96. PubMed ID: 15172082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
